Cargando…

Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia

Multidrug resistance (MDR) development has emerged as a complication that compromises the success of several chemotherapeutic agents. In chronic myeloid leukemia (CML), imatinib resistance has been associated with changes in BCR-ABL1 and intracellular drug concentration, controlled by SLC and ABC tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alves, Raquel, Gonçalves, Ana Cristina, Jorge, Joana, Almeida, António M., Sarmento-Ribeiro, Ana Bela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138473/ https://www.ncbi.nlm.nih.gov/pubmed/35625893 http://dx.doi.org/10.3390/biomedicines10051158

Ejemplares similares

P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB
por: Alves, Raquel, et al.
Publicado: (2023)

Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines
por: Alves, Raquel, et al.
Publicado: (2023)

Zinc Prevents DNA Damage in Normal Cells but Shows Genotoxic and Cytotoxic Effects in Acute Myeloid Leukemia Cells
por: Costa, Maria Inês, et al.
Publicado: (2022)

Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis
por: Alves, Raquel, et al.
Publicado: (2022)

Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation
por: Jorge, Joana, et al.
Publicado: (2022)

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
por: Alves, Raquel, et al.
Publicado: (2021)

PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
por: Jorge, Joana, et al.
Publicado: (2023)

PB1822: INHIBITION OF THE DNA DAMAGE RESPONSE: A POSSIBLE NEW ROUTE IN ACUTE MYELOBLASTIC LEUKEMIA TREATMENT
por: Lapa, Beatriz, et al.
Publicado: (2023)

AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells
por: Lapa, Beatriz Santos, et al.
Publicado: (2023)

PB1908: NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY
por: Jorge, Joana, et al.
Publicado: (2023)

Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies
por: Jorge, Joana, et al.
Publicado: (2023)

Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α
por: Alves, Raquel, et al.
Publicado: (2020)

P841: MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY
por: Alves, Raquel, et al.
Publicado: (2023)

PB1782: ZINC IN THE MODULATION OF THE ANTIPROLIFERATIVE AND CYTOTOXIC EFFECTS OF OLAPARIB IN ACUTE MYELOID LEUKEMIA
por: Costa, M. I., et al.
Publicado: (2022)

Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
por: Scerni, Ana Carolina Costa, et al.
Publicado: (2009)

PB1719: NIRAPARIB IN B-CELL LYMPHOID MALIGNANCIES: EXPLORING SYNTHETIC LETHALITY AS TARGET FOR THERAPY
por: Lapa, Beatriz, et al.
Publicado: (2023)

Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase
por: Malhotra, Hemant, et al.
Publicado: (2015)

Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters
por: Omran, Mervat M., et al.
Publicado: (2022)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Platelet Membrane Proteins as Pain Biomarkers in Patients with Severe Dementia
por: Ribeiro, Hugo, et al.
Publicado: (2023)

Monocytes in the Characterization of Pain in Palliative Patients with Severe Dementia—A Pilot Study
por: Ribeiro, Hugo, et al.
Publicado: (2023)

MicroRNA signature refine response prediction in CML
por: Alves, Raquel, et al.
Publicado: (2019)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)

The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid
por: Karbownik, Agnieszka, et al.
Publicado: (2019)

Recombinant trail: a synergistic effect in myeloid leukemias
por: Carvalho, Filipa, et al.
Publicado: (2010)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells
por: Yang, Yuefeng, et al.
Publicado: (2015)

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment
por: Angriman, Federico, et al.
Publicado: (2015)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring
por: Martins, Ivana, et al.
Publicado: (2021)

Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients
por: Gonçalves, Ana Cristina, et al.
Publicado: (2021)

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar()
por: Sawicki, Emilia, et al.
Publicado: (2016)

The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice
por: Vicente, Belén, et al.
Publicado: (2021)

Nano‐gold micelles loaded Dox and Elacridar for reversing drug resistance of breast cancer
por: Wen, Liu‐Jing, et al.
Publicado: (2022)

Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients
por: Chhikara, S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ue7v3621h3oov973p907trcea8